Author(s): Lindvall O, Hyun I
Abstract Share this page
Abstract Stem cell tourism is criticized on grounds of consumer fraud, blatant lack of scientific justification, and patient safety. However, the issues are complex because they invoke questions concerning the limits of acceptable medical innovation and medical travel. Here we discuss these issues and articulate conditions under which "unproven" therapies may be offered to patients outside of regular clinical trials.
This article was published in Science
and referenced in Journal of Business & Financial Affairs